US2021228533A1PendingUtilityA1

Pharmaceutical composition, methods for treating and uses thereof

71
Assignee: BOEHRINGER INGELHEIM INTPriority: Nov 10, 2016Filed: Nov 10, 2020Published: Jul 29, 2021
Est. expiryNov 10, 2036(~10.3 yrs left)· nominal 20-yr term from priority
Inventors:Maximilian Von EynattenUli Christian BroedlHans-Juergen Woerle
A61K 2300/00A61P 9/00A61K 45/06A61K 31/155A61K 31/522A61P 13/12A61K 31/7048A61K 9/2018A61K 31/351
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

Claims

exact text as granted — not AI-modified
1 . A method of treating, reducing the risk of or slowing the progression of chronic kidney disease in a patient with chronic kidney disease, said method comprising administering empagliflozin to the patient. 
     
     
         2 . The method of  claim 1 , wherein the method additionally reduces the risk of cardiovascular death in the patient. 
     
     
         3 . The method of  claim 1 , wherein the method additionally reduces the risk of all-cause mortality in the patient. 
     
     
         4 . The method of  claim 1 , wherein the method additionally reduces the risk of all-cause hospitalization in the patient. 
     
     
         5 . The method of  claim 1 , wherein the patient has moderately to severely decreased renal function. 
     
     
         6 . The method of  claim 1 , wherein the patient has elevated albuminuria levels ≥200 mg/g. 
     
     
         7 . The method of  claim 1 , wherein the patient has an eGFR≥20 to <45 mL/min/1.73 m 2 . 
     
     
         8 . The method of  claim 1 , wherein the patient has an eGFR≥20 mL/min/1.73 m 2  and a urinary albumin-to-creatine ratio (UACR)≥200 mg/g. 
     
     
         9 . The method of  claim 1 , wherein the patient has an eGFR≥45 and <90 ml/min/1.73 m 2  and a urinary albumin-to-creatine ratio (UACR)≥200 mg/g. 
     
     
         10 . The method of  claim 1 , wherein the patient is treated with a RAAS inhibitor. 
     
     
         11 . The method of  claim 1 , wherein the patient is treated with an Angiotensin-Converting Enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB). 
     
     
         12 . The method of  claim 1 , wherein the patient is a non-diabetic patient. 
     
     
         13 . The method of  claim 1 , wherein the patient is a non-diabetic and non-pre-diabetic patient. 
     
     
         14 . The method of  claim 1 , wherein the patient is a patient with pre-diabetes or a patient with type 2 or type 1 diabetes mellitus. 
     
     
         15 . The method of  claim 1 , wherein empagliflozin is administered at a dose in a range from 1 mg to 25 mg. 
     
     
         16 . The method of  claim 1 , wherein empagliflozin is administered at a dose of 10 mg or 25 mg. 
     
     
         17 . The method of  claim 1 , wherein empagliflozin is administered once daily to the patient.

Join the waitlist — get patent alerts

Track US2021228533A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.